Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Forums: Live Discussions
What We Know, What We Don't Know
back to table  

 

What we know

What we don’t know

22.

Basal forebrain cholinergic neurons are selectively vulnerable in early AD

What causes this vulnerability? What downstream events are triggered by it?


Comments
  Comment by:  Jurgen Claassen (Disclosure)
Submitted 8 May 2007  |  Permalink Posted 1 June 2007

In addition to the cognitive effects (explained by loss of cholinergic innervation to these neuronal structures), there may also be a loss of neurovascular coupling in these regions because cholinergic-vascular innervation is reduced.

References:
Claassen JA and Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.J Gerontol A Biol Sci Med Sci. 2006;61(3):267-71. Abstract

View all comments by Jurgen Claassen

  Comment by:  Paul Coleman, ARF Advisor
Submitted 24 June 2007  |  Permalink Posted 26 June 2007

One of the interesting aspects of cholinergic degeneration in AD is that, although basal forebrain cholinergic neurons degenerate in AD, brain stem cholinergic neurons are basically unaffected (Woolf et al., 1989). Why might this be so? Is it due to differences in projection regions? May it be due to "intrinsic" differences in gene expression profile between these two regions? Understanding of the differences between these two regions could lead to improved therapeutic intervention targeting the affected cholinergic system. For a description of differential gene expression profiles between these two regions see a forthcoming paper in Neurobiology of Aging in which M. McKinney is senior author. (Disclosure: I am also an author of this ms.)

References:
Woolf NJ. Jacobs RW. Butcher LL. The pontomesencephalotegmental cholinergic system does not degenerate in Alzheimer's disease. Neuroscience Letters. 1989;96(3):277-82. Abstract

View all comments by Paul Coleman

  Comment by:  Rafael Rodríguez Puertas
Submitted 26 December 2007  |  Permalink Posted 8 January 2008

There has been described a selective cholinergic alteration in the basal forebrain of AD patients and the areas innervated by these cells, mainly hippocampus and entorhinal cortex. However , tau hyperphosphorylation and amyloidβ protein accumulation seem to start in the projection areas. To me, one of the main questions in AD neurochemistry that has not been answered yet is: what is the chronological order? In other words, is the cholinergic degeneration a previous event to the posterior accumulation of neurofibrilary tangles and senile plaques? Or, on the contrary, is the cholinergic degeneration a consequence? To the best of my knowledge, there is no conclusive study to answer this important question.

View all comments by Rafael Rodríguez Puertas
  Submit a Comment

 
Cast your vote and/or make a comment on this page. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Polls
 
Should the FDA be allowed to use data from overseas clinical trials?

Absolutely, we are running out of viable subjects in the U.S.
 9
 
Yes, so long as the data is reliable
 31
 
No, the trials are not as rigorous
 3
 
No, the data should be repeated in the U.S.
 5
 
No, the drug sponsors are just trying to cut corners
 3
 
Responses: 51
 
 
 
 
 
Archived Polls
 
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad